<DOC>
	<DOCNO>NCT00467142</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , bevacizumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Bevacizumab may also stop growth colorectal cancer block blood flow tumor . Drugs use chemotherapy , irinotecan , leucovorin , fluorouracil , work different way stop growth tumor cell , either kill cell stop divide . Giving bevacizumab together combination chemotherapy may kill tumor cell . PURPOSE : This phase II trial study well give bevacizumab together combination chemotherapy work first-line therapy treat patient metastatic colorectal cancer remove surgery .</brief_summary>
	<brief_title>Bevacizumab Combination Chemotherapy First-Line Therapy Treating Patients With Metastatic Colorectal Cancer That Can Be Removed Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine efficacy bevacizumab , irinotecan hydrochloride , leucovorin calcium , fluorouracil , term partial complete response , patient unresectable metastatic colorectal cancer . Secondary - Determine duration response patient treat regimen . - Determine overall survival progression-free survival patient treat regimen . - Determine tolerability regimen patient . - Assess pharmacogenetics change genetic polymorphism susceptible modification regimen . OUTLINE : This nonrandomized , multicenter study . Patients receive irinotecan hydrochloride IV 90 minute , leucovorin calcium IV 2 hour , bevacizumab IV day 1 . Patients also receive fluorouracil IV 46 hour begin day 1 . Treatment repeat every 2 week absence disease progression unacceptable toxicity . Blood tissue sample collect periodically pharmacogenetic genetic polymorphism analysis . PROJECTED ACCRUAL : A total 61 patient accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma colon rectum No histological type Metastatic , unresectable disease No bone metastases Unidimensionally measurable metastatic disease No CNS metastases PATIENT CHARACTERISTICS : WHO performance status ( PS ) 02 OR Karnofsky PS 70100 % Life expectancy ≥ 12 week ANC &gt; 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 10 g/dL Bilirubin ≤ 1.25 time normal ( 1.5 time normal presence hepatic metastasis ) AST ALT &lt; 3 time normal ( 5 time normal presence hepatic metastasis ) Creatinine &lt; 1.25 time normal No proteinuria Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No cancer past 5 year except carcinoma situ uterine cervix basal cell skin cancer No hypersensitivity fluorouracil No hypersensitivity leucovorin calcium , bevacizumab , excipients No hypersensitivity Chinese hamster ovarian cell product recombinant humanize nonhumanized monoclonal antibody No allergy irinotecan hydrochloride No prior reaction attenuate vaccine ( fever , jaundice ) No poor nutritional status No Biermer anemia anemia due vitamin B12 deficiency No uncontrolled symptomatic occlusion subocclusion No medullary hypoplasia severe insufficiency No prior chronic intestinal disease No Gilbert 's syndrome No intraabdominal inflammatory reaction ( e.g. , gastroduodenal ulcer , diverticulitis , colitis ) No chronic intestinal inflammatory disease No thromboembolic arterial condition past 6 month , include follow : Cardiovascular accident Transient ischemic attack Myocardial infarction No infection serious noncancerous disease No condition unstable would increase risk patient , include follow : Unstable angina Poorly control hypertension Severe cardiac insufficiency Serious arrhythmia Bleeding diathesis Pulmonary disease risk decompensation No familial , geographical , social , psychological condition would preclude study participation No prisoner patient without guardian PRIOR CONCURRENT THERAPY : At least 8 week since prior surgery At least 6 month since prior adjuvant chemotherapy At least 1 month since prior palliative chemotherapy No prior abdominal pelvic radiotherapy At least 30 day since prior participation another investigational study No prior bevacizumab No extensive intestinal resection ( e.g. , partial colectomy extensive thin resection ) No concurrent warfarin , Hypericum perforatum ( St. John 's wort ) , prophylactic phenytoin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
</DOC>